Antiphospholipid Syndrome

Disease-a-Month

Volumn 49, Issue 12, 2003, Pages 691-741

  Orlowski, Janis M ^b   Gezer, Sefer ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CARDIOLIPIN ANTIBODY; CYCLOPHOSPHAMIDE; HEPARIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; LIVER ENZYME; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHATIDYLSERINE; PREDNISONE; STEROID; VIPER VENOM; WARFARIN;

ADRENAL INSUFFICIENCY; ADULT; AGED; ANTIBODY TITER; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; AUTOIMMUNE DISEASE; BLEEDING; BRAIN ISCHEMIA; CHRONIC DISEASE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; ETHNIC GROUP; EVALUATION; FEMALE; FETUS WASTAGE; HUMAN; INCIDENCE; INFARCTION; INTERNATIONAL STANDARD UNIT; KIDNEY BIOPSY; KIDNEY DISEASE; LIVEDO RETICULARIS; LUNG EMBOLISM; MALE; MICROTHROMBUS; NEGRO; OBSTETRICS; PLASMAPHERESIS; PREGNANCY COMPLICATION; PREVALENCE; RACE; RECURRENT DISEASE; RESPIRATORY FAILURE; REVIEW; SPLENECTOMY; SPONTANEOUS ABORTION; STROKE; SYNDROME DELINEATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS; VASCULAR DISEASE; VEIN THROMBOSIS; WORLD HEALTH ORGANIZATION;

EID: 0346992337     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-5029(03)00184-6     Document Type: Review

References (161)

1. Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH, Machin SJ, Barquinero J, et al. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989;68:366-74.
2. Bick RL. Hypercoagulability and thrombosis. Med Clin North Am 1994;78:635-65.
3. Bick RL. Antiphospholipid thrombosis syndromes: etiology, pathophysiology, diagnosis and management. Int J Hematol 1997;65:193-213.
4. Rand JH. The antiphospholipid syndrome. Annu Rev Med 2003;54:409-24.
5. Bick RL. Antiphospholipid thrombosis syndrome. Clin Appl Thromb Haemost 2001;7:241-58.
6. Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952;31: 621-2.
7. Bowie EJW, Thompson JH, Pascuzzi CA, Owen CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963;62:416-30.
8. Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemost Thromb 1972;1:75-95.
9. Nilsson IM, Astedt B, Hedner U, Berezine D. Intrauterine death and circulating anticoagulant "antithromboplastin." Acta Med Scand 1975;197:153-9.
10. Hughes GR. The anticardiolipin syndrome [editorial]. Clin Exp Rheumatol 1985;3:285-6.
11. Harris EN, Hughes GR, Gharavi AE. Antiphospholipid antibodies: an elderly statesman dons new garments. J Rheumatol 1987;13(suppl 14):208-13.
12. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-63.
13. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000;15:145-51.
14. Schved JF, Dupuy-Fons C, Biron C, Quere I, Janbon C. A prospective epidemiological study on the occurrence of antiphospholipid antibody: the Montpellier Antiphospholipid (MAP) study. Hemostasis 1994;24:175-82.
15. Vila P, Hernandez MC, Lopez-Fernandez MF, Batlle J. Prevalence follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994;72:209-13.
16. Bick RL, Jakway J, Baker WF Jr. Deep vein thrombosis: prevalence of etiologic factors and results of management in 100 consecutive patients. Semin Thromb Hemost 1992;18:267-74.
17. Merkel PA, Chang Y, Pierangeli SS, Convery K, Harris EN, Polisson RP. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 1996;101: 576-83.
18. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine 1993;72:113-24.
19. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: prevalence and clinical significance. Ann Intern Med 1990; 112:682-98.
20. Alarćon-Segovia D, Perez-Vasquez ME, Vila AR, Drenkard C, Cabiedes J. Preliminary classification criteria for antiphospholipid syndrome within systemic lupus erytematosus. Semin Arthritis Rheum 1992;21:275-86.
21. Bevers EM, Galli M. Cofactors involved in the antiphospholipid syndrome [editorial]. Lupus 1992;1:51-3.
22. Permpikul P, Rao LV, Rapaport SI. Functional and binding studies of the roles of prothrombin and beta-2-glycoprotein I in the expression of lupus anticoagulant activity. Blood 1994;83:2878-92.
23. Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erytematosus. Lancet 1983;2:1211-4.
24. Goldstein R, Moulds JM, Smith CD, Sengar DP. MHC studies of the primary antiphospholipid antibody syndrome and of antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 1996;23:1173-9.
25. Meroni PL, Raschi E, Camera M, Testoni C, Nicoletti F, Tincani A, et al. Endothelial activation by aPL: a potential pathogenic mechanism for the clinical manifestations of the syndrome. J Autoimmun 2000;15:237-40.
26. Ames PR. Antiphospholipid antibodies, thrombosis and atherosclerosis in systemic lupus erythematosus: a unifying "membrane stress syndrome" hypothesis. Lupus 1994;3:371-7.
27. Oosting JD, Derksen RH, Bobbink IW, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993;81:2618-25.
28. Kandiah DA, Krilis SA. Beta-2-glycoprotein I. Lupus 1994;3:207-12.
29. Long AA, Ginsberg JS, Brill-Edwards P, Johnston M, Turner C, Denburg JA, et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost 1991;66: 520-4.
30. Provenzale JM, Ortel TL, Allen NB. Systemic thrombosis in patients with antiphospholipid antibodies: lesion distribution and imaging findings. AJR Am J Roentgenol 1998;170:285-90.
31. Vianna JL, Khamastha MA, Ordi-Ros J, Font J, Cervera R, Lopez-Soto A, et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med 1994;96:3-9.
32. Bick RL, Baker WF. Anticardiolipin antibodies and thrombosis. Hematol Oncol Clin North Am 1992;6:1287-99.
33. Bick RL, Baker WF. Antiphospholipid syndrome and thrombosis. Semin Thromb Hemost 1999;25:333-50.
34. Ginsburg KS, Liang MH, Newcomer L, Golhaber SZ, Schur PH, Hennekens CH, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117:997-1002.
35. Boey ML, Colaco CB, Gharavi AE, Elkon KB, Loizou S, Hughes GR. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J 1983;287:1021-3.
36. Elias M, Eldor A. Thromboembolism in patients with the "lupus-like"-type circulating anticoagulant. Arch Intern Med 1984;144:510-5.
37. Hall S, Buettner H, Luthra HS. Occlusive retinal vascular disease in systemic lupus erytematosus. J Rheumatol 1984; 11: 846-50.
38. Girolami A, Zanon E, Zanardi S, Saracino MA, Simioni P. Thromboembolic disease developing during oral contraceptive therapy in young females with antiphospholipid antibodies. Blood Coagulation Fibrinolysis 1996;7:497-501.
39. Schutt M, Kluter H, Hagedorn-Greiwe M, Fehm HL, Wiedemann GJ. Familial coexistence of primary antiphospholipid syndrome and factor V Leiden. Lupus 1998;7:176-82.
40. Poux JM, Boudet R, Lacroix P, Jauberteau MO, Plouin PF, Aldigier JC, et al. Renal infarction and thrombosis of the infrarenal aorta in a 35-year-old man with primary antiphospholipid syndrome. Am J Kidney Dis 1996;27:721-5.
41. Kojima E, Naito K, Iwai M, Hirose Y, Isobe K, Takano K. Antiphospholipid syndrome complicated by thrombosis of the superior mesenteric artery: co-existence of smooth muscle hyperplasia. Intern Med 1997;36:528-31.
42. Brey RL, Hart RG, Sherman DG, Tegeler CH. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990;40:1190-6.
43. Toschi V, Motta A, Castelli C, Paracchini ML, Zerbi D, Gibelli A. High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause. Stroke 1998;29:1759-64.
44. Nencini P, Baruffi MC, Abbate R, Massai G, Amaducci L, Inzitari D. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 1992;23:189-93.
45. Briley DP, Coull BM, Goodnight SH Jr. Neurological diseases associated with antiphospholipid antibodies. Ann Neurol 1989;25:221-7.
46. Weingarten K, Filippi C, Barbut D, Zimmerman RD. The neuroimaging features of the cardiolipin antibody syndrome. Clin Imag 1997;21:6-12.
47. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Neurology 1993;43:2069-73.
48. Carhuapoma JR, Mitsias P, Levine SR. Cerebral venous thrombosis and anticardiolipin antibodies. Stroke 1997;28:2363-9.
49. Asherson RA, Khamatsa MA, Hughes GR. Sneddon's syndrome. Neurology 1989;39:1138-9.
50. Frampton G, Winer JB, Cameron JS, Hughes RA. Severe Guillain-Barré syndrome: an association with IgA anti-cardiolipin antibody in a series of 92 patients. J Neuroimmunol 1988;19:133-9.
51. Levin SR, Welch KM. The spectrum of neurologic disease associated with anticardiolipin antibodies: lupus aticoagulants and anticardolipin antibodies. Arch Neurol 1987;44:876-83.
52. Oppenheimer S, Hoffbrand BI. Optic neuritis and myelopathy in systemic lupus erytematosus. Can Neurol Sci 1986;13:129-32.
53. Asherson RA, Morgan SH, Harris EN, Gharavi A, Krausz T, Hughes GR. Arterial occlusion causing large bowel infarction: a reflection of clotting diathesis in SLE. Clin Rheumatol 1986;5:102-6.
54. Hamilton ME. Superior mesenteric artery thrombosis associated with antiphospholipid syndrome. West J Med 1991;155:174-6.
55. Asherson RA, Harris EN, Gharavi AE, Englert HE, Hughes GR. Aortic arch syndrome associated with anticardiolipin antibodies and the lupus anticoagulant. Arthritis Rheum 1985;28:594-5.
56. Asherson RA, Morgan SH, Harris EN, Gharavi AE, Krausz T, Hughes JR. Arterial occlusion causing large bowel infarction: a reflection of clotting diathesis in SLE. Clin Rheumatol 1986;5:102-6.
57. Asherson RA, MacKay IR, Harris EN. Myocardial infarction in a young male with systemic lupus erythematosus, deep vein thrombosis and antiphospholipid antibodies. Br Heart J 1986;56:190-3.
58. Vaarala O. Antiphospholipid antibodies and myocardial infarction. Lupus 1998; 7(suppl 2):S132-4.
59. Gavaghan TP, Krilis SA, Daggard GE, Baron DW, Hickie JB, Chesterman CN. Anticardiolipin antibodies and occlusion of coronary artery bypass grafts. 1987;2:977-8.
60. Morton KT, Gavaghan S, Kirilis SA, Daggard GE, Baron DW, Hickie JB, et al. Coronary artery bypass graft failure: an autoimmune phenomenon? Lancet 1986;2:1353-7.
61. Ludia C, Domenico P, Monia C, Emilia A, Sandra F, Agatina AL, et al. Antiphospholipid antibodies: a new risk factor for restenosis after percutaneous transluminal coronary angioplasty? Autoimmunity 1998;27:141-8.
62. Galve E, Ordi J, Barquinero J, Evangelista A, Vilardell M, Soler-Soler J. Valvular heart disease in primary antiphospholipid syndrome. Ann Intern Med 1992;116:293-8.
63. Chartash EK, Lans DM, Paget SA, Qamar T, Lockshin MD. Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipd syndrome. Am J Med 1989;86:407-12.
64. Chartash EK, Lans DM, Paget SA, Qamar T, Lockshin MD. Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Med 1989;86:407-12.
65. Leung WH, Wong KL, Lau CP, Wong CK, Liu HW. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 1990;89:411-9.
66. Nesher G, Ilany J, Rosenmann D, Abraham AS. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum 1997;27:27-35.
67. Bulckaen HG, Puisieux FL, Bulckaen ED, Di Pompoe C, Bouillanne OM, Watel AA, et al. Antiphospholipid antibodies and the risk of thromboembolic events in valvular heart disease. Mayo Clin Proc 2003;78:294-8.
68. Nzerue CM, Hewan-Lowe K, Pierangeli S, Harris EN. "Black swan in the kidney:" renal involvement in the antiphospholipid antibody syndrome. Kidney Int 2002; 62:733-44.
69. Isom R, Nickolas TL, Radhakrishnan J. Nephrological and obstetric complications of the antiphospholipid syndrome. Expert Opin Investig Drugs 2002; 11:819-29.
70. Nochy D, Daugas E, Hill G, Grunfeld JP. Antiphospholipid syndrome nephropathy. J Nephrol 2002;15:446-61.
71. Luzzana C, Gerosa M, Riboldi P, Meroni PL. Up-date on the antiphospholipid syndrome. J Nephrol 2002;15:342-8.
72. Karmochkine M, Cacoub P, Dorent R, Laroche P, Nataf P, Piette JC, et al. High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension. J Rheumatol 1996;23:286-90.
73. Miyashita Y, Koike H, Misawa A, Shimizu H, Yoshida K, Yasutomi T. Asymptomatic pulmonary hypertension complicated with antiphospholipid syndrome case. Intern Med 1996;35:912-5.
74. Kerr JE, Poe R, Kramer Z. Antiphospholipid antibody syndrome presenting as a refractory noninflammatory pulmonary vasculopathy. Chest 1997;112:1707-10.
75. Lee HJ, Park JW, Chang JC. Mesenteric and portal venous obstruction associated with primary antiphospholipid antibody syndrome. J Gastroenterol Hepatol 1997; 12:822-6.
76. Biron C, Andreani H, Blanc P, Ramos J, Ducos J, Guigue N, et al. Prevalence of antiphospholipid antibodies in patients with chronic liver disease related to alcohol or hepatitis C virus: correlation with liver injury. J Lab Clin Med 1998;131:243-50.
77. Vivaldi P, Rossetti G, Galli M, Finazzi G. Severe bleeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome: case report and review of literature. Haematologica 1997;82:345-7.
78. Hudson N, Duffy CM, Rauch J, Paquin JD, Esdaile JM. Catastrophic haemorrhage in a case of paediatric primary antiphospholipid syndrome and factor II deficiency. Lupus 1997;6:68-71.
79. Cuadrado MJ, Mujic F, Munoz E, Khamashta MA, Hughes GR. Thrombocytopenia in the antiphospholipid syndrome. Ann Rheum Dis 1997;56:194-6.
80. Macchi L, Rispal P, Clofent-Sanchez G, Pellegrin JL, Nurden P, Leng B, et al. Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia. Br J Haematol 1997;98:336-41.
81. Asherson RA, Harris EN. Anticardiolipin antibodies: clinical associations. Post-grad Med J 1986;62:1081-7.
82. Weinstein C, Miller M, Axtens R, Buchanan R, Littlejohn GO. Livido reticularis associated with increased titers of anticardiolipin antibodies in systemic lupus erythematosus. Arch Dermatol 1987;123:596-600.
83. Eng AM. Cutaneous expressions of antiphospholipid syndrome. Semin Thromb Heamost 1994;20:71-8.
84. Wolf P, Peter-Soyer H, Auer-Grumbach P, Kerl H. Widespread cutaneous necrosis in a patient with rheumatoid arthritis associated with anticardiolipin antibodies. Arch Dermatol 1991;127:1739-40.
85. Lockwood CJ, Rand JH. The immunobiology and obstetrical consequences of antiphospholipid antibodies. Obstet Gynecol Surv 1994;49:432-41.
86. Greaves M, Cohen H, MacHin SJ, Mackie I, et al. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000;109:704-15.
87. Arkel YS, Ku DHW. Thrombophilia and pregnancy: review of the literature and some original data. Clin Appl Thromb Hemost 2001;7:259-68.
88. Erkan D. The relation between antiphospholipid syndrome-related pregnancy morbidity and non-gravid vascular thrombosis: a review of the literature and management strategies. Curr Rheumatol Rep 2002;4:379-86.
89. Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol 2003;101:1333-44.
90. Lockshin MD, Druzin ML, Goei S, Qamar T, Magid MS, Jovanovic L, et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med 1985;313:152-6.
91. Oshiro BT, Silver RM, Scott JR, Yu H, Branch DW. Antiphospholipid antibodies and fetal death. Obstet Gynecol 1996;87:489-93.
92. Harris NE, Spinnato JA. Should anticardiolipin tests be performed in otherwise healthy pregnant women? Am J Obstet Gynecol 1991;165:1272-7.
93. Feinstein DI. Lupus anticoagulant, anticardiolipin antibodies, fetal loss and systemic lupus erythematosus. Blood 1992;80:859-62.
94. di Somone N, Meroni PL, de Papa N, Raschi E, Caliandro D, De Carolis CS, et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta 2-glycoprotein I. Arthritis Rheum 2000;43:140-50.
95. Rand JH, Wu X-X, Andree HA, Lockwood CJ, Guller S, Scher C, et al. Pregnancy loss in the antiphospholipid-antibody syndrome: a possible thrombogenic mechanism. N Engl J Med 1997;337:154-60.
96. Donohoe S, Kingdom JC, Mackie IJ, Burrell S, Quenby S, Jauniaux E, Machin SJ, et al. Ontogeny of beta2-glycoprotein I and annexin V in villous placenta of normal and antiphospholipid pregnancies. Thromb Haemost 2000;84:32-8.
97. Asherson RA. The catastrophic antiphospholipid syndrome, 1998: a review of the clinical features, possible pathogenesis and treatment. Lupus 1998;7(suppl 2):S55-62.
98. Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, et al. Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998;77:195-207.
99. Westney GE, Harris EN. Catastrophic antiphospholipid syndrome in the intensive care unit. Crit Care Clin 2002;18:805-17.
100. Espinosa G, Santos E, Cervera R, Piette JC, de la Red G, Gil V, et al. Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients. Medicine 2003;82:106-18.
101. Kitchens CS. Thrombotic storm: when thrombosis begets thrombosis. Am J Med 1998;104:381-5.
102. Intrator L, Oksenhendler E, Desforges L, Bierling P. Anticardiolipin antibodes in HIV infected patients with or without immune thrombocytopenic purpura. Br J Haematol 1988;67:269-70.
103. Asherson RA, Shoenfeld Y. Human immunodeficiency virus infection, antiphospholipid antibodies, and the antiphospholipid syndrome [editorial]. J Rheumatol 2003;30:214-9.
104. Canoso RT, Zon LI, Groopman JE. Anticardiolipin antibodies associated with HTLV-III infection. Br J Haematol 1987;65:495-8.
105. Panzer S, Stain C, Hartl H, Dudczak R, Lechner K. Anticardiolipin antibodies are elevated in HIV-1 infected haemophiliacs but do not predict for disease progression. Thromb Haemost 1989;61:81-5.
106. Stimmler MM, Quismorio FP Jr, McGehee WG, Boylen T, Sharma OP. Anticardiolipin antibodies in acquired immune deficiency syndrome. Arch intern Med 1989;149:1833-5.
107. Vaarala O, Palosuo T, Kleemola M, Aho K. Anticardiolipin response in acute infections. Clin Immunol Immunopathol 1986;41:8-15.
108. Violi F, Ferro D, Quintarelli C, Alessandri C, Saliola M, Valesini G. Dilute aPTT prolongation by antiphospholipid antibodies in patients with liver cirrhosis. Thromb Haemost 1990;63:183-6.
109. Harrison RL, Alperin JP, Kumar D. Concurrent lupus anticoagulants and prothrombin deficiency due to phenytoin use. Arch Pathol Lab Med 1987;111:719-22.
110. Lillicrap DP, Pinto M, Benford K, Ford PM, Ford S. Heterogeneity of laboratory test results for antiphospholipid antibodies in patients treated with chlorpromazine and other phenothiazines. Am J Clin Pathol 1990;93:771-5.
111. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definitive antiphospholipid syndrome. Atrhritis Rheum 1999;42:1309-11.
112. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995;74:1185-90.
113. Alarcón-Segovia D, Delezé-Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, et al. Antiphospholipid antibodies and antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989;68:353-65.
114. Alarcón-Segovia D, Sanchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989;16:482-8.
115. Hughson MD, McCarty GA, Brumback RA. Spectrum of vascular pathology affecting patients with antiphospholipid syndrome. Hum Pathol 1995;26:716-24.
116. Lie JT. Pathology of antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette J-C, Shoenfeld Y, editors. The antiphospholipid syndrome. Boca Raton (Fla): CRC press; 1996:p 89-104.
117. Laflan MA, Bradshaw AE. Investigation of hemostasis. In: Dacie JV, Lewis SM, editors. Practical hematology. 8th ed.. New York: Churchill Livingstone; 1995. p 298-99.
118. Hathaway WE, Goodnight SH Jr. Disorders of hemostasis and thrombosis. New York: McGraw-Hill; 1993.
119. Galli M, Barbui T. Prothrombin as cofactor for antiphospholipids. Lupus 1998; 7(suppl 2):S37-40.
120. Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies. Blood 1995;86:617-23.
121. Arnout J, Vanrusselt M, Huybrechts E, Vermylen J. Optimization of the dilute prothrombin time for the detection of lupus anticoagulant by use of a recombinant human tissue thromboplastin. Br J Heamatol 1994;87:94-9.
122. Liu HW, Wong KL, Lin CK, Wong WS, Tse PW, Chan GT. The reappraisal of dilute tissue thromboplastin inhibition test in the diagnosis of lupus anticoagulant. Br J Haematol 1989;72:229-34.
123. Forastiero RR, Cerrato GS, Carreras LO. Evaluation of recently described tests for detection of the lupus anticoagulant. Thromb Haemost 1994;72:728-33.
124. Sanmarco M, Soler C, Christides C, Raoult D, Weiller PJ, Gerolami V, et al. Prevalence and clinical significance of IgG isotype anti-beta 2-glycoprotein I antibodies in antiphospholipid syndrome: a comparative study with anticardiolipin antibodies. J Lab Clin Med 1997;129:499-506.
125. Zanon E, Prandoni P, Vianello F, Saggiorato G, Carraro G, Bagatella P, et al. Anti-beta2-glycoprotein I antibodies in patients with acute venous thromboembolism: prevalence and association with recurrent thromboembolism. Thromb Res 1999;96:269-74.
126. Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I: Identity with annexin II. J Biol Chem 1994;269: 21191-7.
127. Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II: Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem 1994;269:21198-203.
128. Lenzi R, Rand JH, Spiera H. Anticardiolipin antibodies in pregnant patients with systemic lupus erythematosus [letter]. N Engl J Med 1986;314:1392-3.
129. McCrae KR. Antiphospholipid antibody associated thrombosis: a consensus for treatment? Lupus 1996;5:560-70.
130. Urfer C, Pichler WJ, Helbling A. Antiphospholipid antibodies syndrome: follow-up of patients with a high antiphospholipid antibodies titer. Schweiz Med Wochenschr 1996;126:2136-40.
131. Erkan D, Merrill JT, Yazici Y, Sammaritano L, Buyon JP, Lockshin MD. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum 2001;44:1466-7.
132. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996;5(suppl 1):S16-22.
133. Wallace DJ. The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus 1996;5(suppl 1):S59-64.
134. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993-7.
135. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117:303-8.
136. Derksen RH, de Groot PG, Kater L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 1993;52:689-92.
137. Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995;86:3685-91.
138. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998;104:332-8.
139. Douketis JD, Crowther MA, Julian JA, Stewart K, Donovan D, Kaminska EA, et al. The effects of low-intensity warfarin on coagulation activation in patients with antiphospholipid antibodies and systemic lupus erythematosus. Thromb Haemost 1999;82:1028-32.
140. Finazzi G, Brancaccio V, Moia M, Ciaverella N, Mazzucconi MG, Schinco PC, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996;100:530-6.
141. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997;127:177-85.
142. Della Valle P, Crippa L, Safa O, Tomassini L, Pattarini E, Vigano-D'Angelo S, et al. Potential failure of the international normalized ratio (INR) system in the monitoring of oral anticoagulation in patients with lupus anticoagulants. Ann Med Interne (Paris) 1996;147(suppl 1):10-4.
143. Le DT, Weibert RT, Sevilla BK, Donnelly KJ, Rapaport SI. The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods. Ann Intern Med 1994;120:552-8.
144. Ciavarella N, Coccheri S, Gensini GF, Hassan HJ, Mannucci PM, Manotti C, et al. Multicenter evaluation of a new chromogenic factor X assay in plasma of patients on oral anticoagulants. Thromb Res 1980;19:493-502.
145. Lind SE, Callas PW, Golden EA, Joyner KA Jr, Ortel TL. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coagulation Fibrinoloysis 1997;8:48-53.
146. Camps Garcia MT, Guil M, Sanchez-Lora J, Grana MI, Martinez J, de Ramon E. Fibrinolytic treatment in primary antiphospholipid syndrome. Lupus 1996;5:627-9.
147. Julkunen H, Hedman C, Kauppi M. Thrombolysis for acute ischemic stroke in the primary antiphospholipid syndrome. J Rheumatol 24:181-3.
148. Ho YL, Chen MF, Wu CC, Chen WJ, Lee YT. Successful treatment of acute myocardial infarction by thrombolytic therapy in a patient with primary antiphospholipid antibody syndrome. Cardiology 1996;87:354-7.
149. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992; 166:1318-23.
150. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996;174:1584-9.
151. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997;314:253-7.
152. Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddell HS, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? a randomized controlled trial. Am J Obstet Gynecol 2000;183:1008-12.
153. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001;119(suppl 1):S122-31.
154. Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999;81:668-72.
155. Ginsberg JS, Hirsh J, Turner DC, Levine MN, Burrows R. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989;61:197-203.
156. Ginsberg JS, Kowalchuk G, Hirsh J, Brill-Edwards P, Burrows R. Heparin therapy during pregnancy: risks to the fetus and mother. Arch Intern Med 1989;149:2233-6.
157. Dulitzki M, Pauzner R, Langevitz P, Pras M, Many A, Schiff E. Low molecular weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol 1996;87:380-3.
158. Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low molecular weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999;181:1113-7.
159. Hunt BJ, Doughty HA, Majumdar G, Copplestone A, Kerslake S, Buchanan N, et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997;77:39-43.
160. Blomback M, Bremme K, Hellgren M, Siegbahn A, Lindberg H. Thromboprophylaxis with low molecular mass heparin, "Fragmin" (dalteparin), during pregnancy: a longitudinal safety study. Blood Coagulation Fibrinolysis 1998;9:1-9.
161. Cowchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial. Am J Obstet Gynecol 1997;176:1099-100.